Towards third generation matrix metalloproteinase inhibitors for cancer therapy

被引：276

作者：

Overall, CM

Kleifeld, O

机构：

[1] Univ British Columbia, Ctr Blood Res, CBCRA Program Breast Ctr Metastasis, Dept Oral Biol, Vancouver, BC V6T 1Z3, Canada

[2] Univ British Columbia, Ctr Blood Res, CBCRA Program Breast Ctr Metastasis, Dept Med Sci, Vancouver, BC V6T 1Z3, Canada

[3] Univ British Columbia, Ctr Blood Res, CBCRA Program Breast Ctr Metastasis, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada

来源：

BRITISH JOURNAL OF CANCER | 2006年 / 94卷 / 07期

关键词：

target validation; antiproteolytic drug; cancer therapy; drug design; zinc chelation;

D O I：

10.1038/sj.bjc.6603043

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The failure of matrix metalloproteinase (MMP) inhibitor drug clinical trials in cancer was partly due to the inadvertent inhibition of MMP antitargets that counterbalanced the benefits of MMP target inhibition. We explore how MMP inhibitor drugs might be developed to achieve potent selectivity for validated MMP targets yet therapeutically spare MMP antitargets that are critical in host protection.

引用

页码：941 / 946

页数：6

共 35 条

[1] Conformational variability of matrix metalloproteinases: Beyond a single 3D structure [J].

Bertini, I ;

Calderone, V ;

Cosenza, M ;

Fragai, M ;

Lee, YM ;

Luchinat, C ;

Mangani, S ;

Terni, B ;

Turano, P .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (15) :5334-5339

[2] A proteomic approach for the discovery of protease substrates [J].

Bredemeyer, AJ ;

Lewis, RM ;

Malone, JP ;

Davis, AE ;

Gross, J ;

Townsend, RR ;

Ley, TJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (32) :11785-11790

[3]

BUTLER G, 2006, IN PRESS CURR PHARM

[4] NOVEL INDOLACTAM-BASED INHIBITORS OF MATRIX METALLOPROTEINASES [J].

CASTELHANO, AL ;

BILLEDEAU, R ;

DEWDNEY, N ;

DONNELLY, S ;

HORNE, S ;

KURZ, LJ ;

LIAK, TJ ;

MARTIN, R ;

UPPINGTON, R ;

YUAN, ZY ;

KRANTZ, A .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1995, 5 (13) :1415-1420

[5] Structure-based design of a novel, potent, and selective inhibitor for MMP-13 utilizing NMR spectroscopy and computer-aided molecular design [J].

Chen, JM ;

Nelson, FC ;

Levin, JI ;

Mobilio, D ;

Moy, FJ ;

Nilakantan, R ;

Zask, A ;

Powers, R .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2000, 122 (40) :9648-9654

[6] Quantum chemistry study on the interaction of the exogenous ligands and the catalytic zinc ion in matrix metalloproteinases [J].

Cheng, F ;

Zhang, RH ;

Luo, XM ;

Shen, JH ;

Li, X ;

Gu, JD ;

Zhu, WL ;

Shen, JK ;

Sagi, I ;

Ji, RY ;

Chen, KX ;

Jiang, HL .

JOURNAL OF PHYSICAL CHEMISTRY B, 2002, 106 (17) :4552-4559

[7] Cancer therapy - Matrix metalloproteinase inhibitors and cancer: Trials and tribulations [J].

Coussens, LM ;

Fingleton, B ;

Matrisian, LM .

SCIENCE, 2002, 295 (5564) :2387-2392

[8] Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs [J].

Cuniasse, P ;

Devel, L ;

Makaritis, A ;

Beau, F ;

Georgiadis, D ;

Matziari, A ;

Yiotakis, A ;

Dive, V .

BIOCHIMIE, 2005, 87 (3-4) :393-402

[9] Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors [J].

Dublanchet, AC ;

Ducrot, P ;

Andrianjara, C ;

O'Gara, M ;

Morales, R ;

Compère, D ;

Denis, A ;

Blais, S ;

Cluzeau, P ;

Courté, K ;

Hamon, J ;

Moreau, F ;

Prunet, ML ;

Tertre, A .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (16) :3787-3790

[10] New functions for the matrix metalloproteinases in cancer progression [J].

Egeblad, M ;

Werb, Z .

NATURE REVIEWS CANCER, 2002, 2 (03) :161-174

← 1 2 3 4 →